State of Tennessee Department of Treasury Sells 35,021 Shares of Hologic, Inc. (NASDAQ:HOLX)

State of Tennessee Department of Treasury trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 40.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,564 shares of the medical equipment provider's stock after selling 35,021 shares during the period. State of Tennessee Department of Treasury's holdings in Hologic were worth $3,789,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in HOLX. TD Waterhouse Canada Inc. boosted its position in Hologic by 62.8% during the 4th quarter. TD Waterhouse Canada Inc. now owns 15,315 shares of the medical equipment provider's stock valued at $1,104,000 after buying an additional 5,908 shares during the period. Tower Research Capital LLC TRC boosted its position in Hologic by 214.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,671 shares of the medical equipment provider's stock valued at $1,202,000 after acquiring an additional 11,377 shares in the last quarter. Thematics Asset Management grew its holdings in shares of Hologic by 0.3% during the 4th quarter. Thematics Asset Management now owns 522,061 shares of the medical equipment provider's stock worth $37,635,000 after acquiring an additional 1,368 shares during the period. Transce3nd LLC bought a new position in Hologic in the fourth quarter worth $96,000. Finally, MetLife Investment Management LLC lifted its position in Hologic by 1.8% during the 4th quarter. MetLife Investment Management LLC now owns 61,409 shares of the medical equipment provider's stock valued at $4,427,000 after acquiring an additional 1,080 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

Shares of HOLX stock traded down $0.16 on Wednesday, hitting $58.20. 2,877,868 shares of the stock traded hands, compared to its average volume of 1,975,716. Hologic, Inc. has a 52 week low of $55.89 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market cap of $13.06 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 2.14 and a beta of 0.82. The firm has a 50 day simple moving average of $60.78 and a two-hundred day simple moving average of $69.69.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HOLX shares. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Needham & Company LLC lowered Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price for the company. in a report on Monday, February 3rd. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Citigroup dropped their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, Evercore ISI lowered their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.